Patent Ductus Arteriosus: Are Current Neonatal Treatment Options Better or Worse Than No Treatment at All?

被引:199
作者
Clyman, Ronald I. [1 ,2 ]
Couto, James [3 ]
Murphy, Gail M. [4 ]
机构
[1] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA
[3] Amer Acad Pediat, Div Hosp & Surg Serv, Elk Grove Village, IL USA
[4] Neonatal Res & Technol Assessment Inc, Burlington, VT USA
关键词
ibuprofen; indomethacin; ligation; PDA management; CEREBRAL-BLOOD-FLOW; BIRTH-WEIGHT INFANTS; PRETERM INFANTS; PREMATURE-INFANTS; RISK-FACTORS; INTRAVENTRICULAR HEMORRHAGE; INDOMETHACIN THERAPY; ECHOCARDIOGRAPHIC PREDICTION; BRONCHOPULMONARY DYSPLASIA; PROPHYLACTIC INDOMETHACIN;
D O I
10.1053/j.semperi.2011.09.022
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Although a moderate-sized patent ductus arteriosus (PDA) needs to be closed by the time a child is 1-2 years old, there is great uncertainty about whether it needs to be closed during the neonatal period. Although 95% of neonatologists believe that a moderate-sized PDA should be closed if it persists in infants (born before 28 weeks) who still require mechanical ventilation, the number of neonatologists who treat a PDA when it occurs in infants who do not require mechanical ventilation varies widely. Both the high likelihood of spontaneous ductus closure and the absence of randomized controlled trials, specifically addressing the risks and benefits of neonatal ductus closure, add to the current uncertainty. New information suggests that early pharmacologic treatment has several important short-term benefits for the preterm newborn. By contrast, ductus ligation, while eliminating the detrimental effects of a PDA on lung development, may create its own set of morbidities that counteract many of the benefits derived from ductus closure. Semin Perinatol 36:123-129 (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:123 / 129
页数:7
相关论文
共 107 条
[1]  
ACHANTI B, 1986, CLIN INVEST MED, V9, P250
[2]   Effect of ibuprofen on bilirubin-albumin binding [J].
Ahlfors, CE .
JOURNAL OF PEDIATRICS, 2004, 144 (03) :386-388
[3]   Prevention and 18-month outcomes of serious pulmonary hemorrhage in extremely low birth weight infants: Results from the trial of indomethacin prophylaxis in preterms [J].
Alfaleh, Khalid ;
Smyth, John A. ;
Roberts, Robin S. ;
Solimano, Alfonso ;
Asztalos, Elizabeth V. ;
Schmidt, Barbara .
PEDIATRICS, 2008, 121 (02) :E233-E238
[4]  
Alpan G, 1995, Surfactant therapy for lung disease: lung biology in health and disease, V84, P531
[5]   Indomethacin use for the management of patent ductus arteriosus in preterms: A web-based survey of practice attitudes among neonatal fellowship program directors in the United States [J].
Amin, S. B. ;
Handley, C. ;
Carter-Pokras, O. .
PEDIATRIC CARDIOLOGY, 2007, 28 (03) :193-200
[6]   Furosemide in preterm infants treated with indomethacin for patent ductus arteriosus [J].
Andriessen, Peter ;
Struis, Nicole C. ;
Niemarkt, Hendrik ;
Oetomo, Sidarto Bambang ;
Tanke, Ronald B. ;
Van Overmeire, Bart .
ACTA PAEDIATRICA, 2009, 98 (05) :797-803
[7]   REGIONAL CEREBRAL BLOOD-FLOW VELOCITY CHANGES AFTER INDOMETHACIN INFUSION IN PRETERM INFANTS [J].
AUSTIN, NC ;
PAIRAUDEAU, PW ;
HAMES, TK ;
HALL, MA .
ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION, 1992, 67 (07) :851-854
[8]  
BANDSTRA ES, 1988, PEDIATRICS, V82, P533
[9]  
Barrington KJ, 2002, Cochrane Database of Systematic Reviews, DOI [DOI 10.1002/14651858.CD003213, 10.1002/14651858.CD003213]
[10]  
Bell EF, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000503